Hansa Biopharma
Develops antibody-cleaving enzyme technology for rare immunologic diseases.
HNSA | ST
Overview
Corporate Details
- ISIN(s):
- SE0002148817 (+1 more)
- LEI:
- 549300LLEO25ZJJ3NT91
- Country:
- Sweden
- Address:
- Box 785, 220 07 Lund
- Website:
- https://www.hansabiopharma.com/
- Sector:
- Manufacturing
Description
Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-19 20:35 |
Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney…
|
English | 247.7 KB | ||
| 2025-12-19 20:35 |
Hansa Biopharma lämnar in BLA-ansökan till FDA för imlifidase för desensitiseri…
|
Swedish | 228.1 KB | ||
| 2025-12-16 23:07 |
Hansa provides update on Pivotal Phase 3 trial in anti-glomerular basement memb…
|
English | 190.6 KB | ||
| 2025-12-16 23:07 |
Hansa ger uppdatering om den registreringsgrundande fas 3-studien för anti-glom…
|
Swedish | 188.6 KB | ||
| 2025-10-31 14:37 | Swedish | 10.7 KB | |||
| 2025-10-31 12:00 |
Hansa Biopharma: Ökning av antalet aktier och röster
|
Swedish | 188.6 KB | ||
| 2025-10-31 12:00 |
Hansa Biopharma: Increase in number of shares and votes
|
English | 190.3 KB | ||
| 2025-10-30 07:00 | Swedish | 1.7 MB | |||
| 2025-10-30 07:00 | English | 2.1 MB | |||
| 2025-10-08 17:06 | Swedish | 10.8 KB | |||
| 2025-10-07 10:02 | Swedish | 10.9 KB | |||
| 2025-10-06 17:53 | Swedish | 10.0 KB | |||
| 2025-10-06 15:46 | Swedish | 10.1 KB | |||
| 2025-10-03 17:20 | Swedish | 12.4 KB | |||
| 2025-10-02 08:30 |
Hansa Biopharma publishes disclosure document for admission to trading of share…
|
English | 193.8 KB |
Automate Your Workflow. Get a real-time feed of all Hansa Biopharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Hansa Biopharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Hansa Biopharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-17 | Anne Säfström Lanner | Other | Sell | 10,487 | 443,285.49 SEK |
| 2024-06-17 | Sören Tulstrup | Other | Sell | 9,199 | 388,841.73 SEK |
| 2024-06-17 | Sören Tulstrup | Other | Buy | 35,200 | N/A |
| 2022-07-19 | Peter Nicklin | Other | Buy | 14,500 | 1,032,192.68 SEK |
| 2022-06-17 | Christian Kjellman | Other | Buy | 6,915 | 345,680.85 SEK |
| 2022-06-17 | Donato Spota | Other | Sell | 4,638 | 231,853.62 SEK |
| 2022-06-17 | Christian Kjellman | Other | Sell | 4,002 | 200,059.98 SEK |
| 2022-06-17 | Sören Tulstrup | Other | Sell | 3,925 | 196,210.75 SEK |
| 2022-06-17 | Sören Tulstrup | Other | Buy | 3,925 | 196,210.75 SEK |
| 2022-06-17 | Anne Säfström Lanner | Other | Sell | 2,685 | 134,223.15 SEK |
Peer Companies
